Constellation Pharmaceuticals Announces Appointments to Board of Directors
04 Septembre 2018 - 12:30PM
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a
clinical-stage biopharmaceutical company using its expertise in
epigenetics to discover and develop novel therapeutics, today
announced that Dr. Elizabeth G. Tréhu and Steven L. Hoerter have
been appointed to its Board of Directors.
Dr. Tréhu is a hematologist / oncologist with 16 years of
management experience at several biopharmaceutical companies.
She is currently Chief Medical Officer at Jounce Therapeutics and
previously served as Chief Medical Officer at Promedior.
Prior to that, she held leadership positions in medical affairs and
program leadership at Infinity Pharmaceuticals, Genzyme and
Millennium Pharmaceuticals. Before working in industry, she
taught at Tufts University and Georgetown University schools of
medicine and treated hematology and oncology patients in private
practice. She earned an A.B. from Princeton University and an
M.D. from New York University School of Medicine.
Since early 2016, Mr. Hoerter has served as Chief Commercial
Officer of Agios Pharmaceuticals, where he built and leads the team
responsible for the commercialization of the company’s portfolio of
medicines for oncology and rare genetic diseases. He has more
than 25 years of global pharmaceutical and biotechnology
experience, having held sales and marketing roles at Roche,
Genentech, Chiron and Eli Lilly. Prior to joining Agios, Mr.
Hoerter was Executive Vice President and Chief Commercial Officer
at Clovis Oncology, Inc., where he built and led the company’s
commercial organization. He earned a B.A. from Bucknell
University, an M.B.A. from Tilburg University in
the Netherlands, and an M.S. in management from Purdue
University.
“We welcome Beth and Steve to the Constellation Board,” said
Jigar Raythatha, President and Chief Executive Officer of
Constellation Pharmaceuticals. “They bring considerable
experience working in the disease areas of myelofibrosis and
prostate cancer that is directly relevant to Constellation’s
clinical programs. We will benefit from their wisdom and
guidance as we work to advance our multiple epigenetic-based
product candidates through clinical development and bring them to
patients in need.”
About Constellation Pharmaceuticals
Constellation Pharmaceuticals is a clinical-stage
biopharmaceutical company using its expertise in epigenetics to
discover and develop novel therapeutics that address serious unmet
medical needs in patients with cancers associated with abnormal
gene expression or drug resistance. With a decade of experience in
the field, the Company has a deep understanding of how epigenetic
regulators modulate gene expression in cancer cells and in the
tumor and immune microenvironment. Constellation is
translating these insights to advance the Company’s two lead
clinical programs, the EZH2 inhibitor CPI-1205 for metastatic
castration-resistant prostate cancer and solid tumors and the BET
inhibitor CPI-0610 for myelofibrosis, and to explore other novel
targets for which cancer epigenetics may enhance outcomes over
currently available treatment options.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of 1995
that involve substantial risks and uncertainties. Any
forward-looking statements are based on management’s current
expectations of future events and are subject to a number of risks
and uncertainties that could cause actual results to differ
materially and adversely from those set forth in, or implied by,
such forward-looking statements. For a discussion of risks
and uncertainties, and other important factors, any of which could
cause the Company’s actual results to differ from those contained
in the forward-looking statements, see the “Risk Factors” section,
as well as discussions of potential risks, uncertainties and other
important factors, in the Company’s most recent filings with
the Securities and Exchange Commission.
ContactRonald Aldridge Investor
RelationsConstellation Pharmaceuticals+1
617-714-0539ron.aldridge@constellationpharma.com
Lauren ArnoldMedia RelationsMacDougall Biomedical
Communications+1 781-235-3060larnold@macbiocom.com
Constellation Pharmaceut... (NASDAQ:CNST)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Constellation Pharmaceut... (NASDAQ:CNST)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024